Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BCR-ABL-negative chronic myeloid leukemia.

Current hematologic malignancy reports - 1 May 2007

Burgstaller Sonja, Reiter Andreas, Cross Nicholas C P

Abstract excerpt

Constitutive activation of protein tyrosine kinases plays a central role in the pathogenesis of myeloproliferative disorders, including BCR-ABL-negative chronic myeloid leukemia. Current research is focused on elucidating the full spectrum of causative mutations in this rare, heterogeneous diseas...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aneuploidy
Share to Enzyme Activation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogene Proteins, Fusion

Share to Protein Kinases

Share to Risk Factors

Share to Signal Transduction

Share to Translocation, Genetic

Source

Identifiers

PMID: 20425354
DOI: 10.1007/s11899-007-0011-5

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20425354-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BCR-ABL-negative chronic myeloid leukemia.PMID 20425354Read ↗

Molecular biology of bcr-abl1–positive chronic myeloid leukemiaSemantic proximity Read ↗

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.Semantic proximity Read ↗

Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.Semantic proximity Read ↗

Molecular and cellular bases of chronic myeloid leukemiaSemantic proximity Read ↗

BCR-ABL: The molecular mastermind behind chronic myeloid leukemiaSemantic proximity Read ↗

Natural course and biology of CML.Semantic proximity Read ↗

Chronic myeloproliferative disorders: a tyrosine kinase tale.Semantic proximity Read ↗

State-of-the-art in the treatment of chronic myeloid leukaemia.Semantic proximity Read ↗

Genetic landscape of chronic myeloid leukemia.Semantic proximity Read ↗

Advances in Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: The Evolving Role of Bcr–Abl Mutations and Mutational AnalysisSemantic proximity Read ↗

Chronic Myeloid Leukemia: Beyond BCR-ABL1Semantic proximity Read ↗

Molecular biology of chronic myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.